Techniclone Announces Appointment of Terrence Chew, M.D. as Vice President, Clinical and Regulatory Affairs.

TUSTIN, Calif.--(BUSINESS WIRE)--Aug. 18, 1999--

Techniclone Corporation (NASDAQ: TCLN) a developer of leading-edge therapeutics for the advanced treatment of cancer, announced today the appointment of Terrence Chew, M.D., as Vice President Clinical and Regulatory Affairs, effective August 30, 1999.

Larry O. Bymaster, President and Chief Executive Officer stated, "We are very pleased that Dr. Chew is joining the Techniclone team. He brings a solid corporate and medical background in clinical development and research, including obtaining FDA approval for several drugs. As an oncologist, Dr. Chew's guidance will be invaluable in assisting the Company to maximize the progress of our Cotara(TM) clinical trials, and the preclinical programs for the Vascular Targeting Agents and Vasopermeation Enhancement Agents."

Dr. Chew is currently Vice President, Clinical Development for SkyePharma Inc., a publicly traded pharmaceutical company, where he developed and guided the clinical development program for a drug that received FDA approval. Prior to SkyePharma Inc., he was Medical Research Director at Agouron Pharmaceuticals. Previous to this, Dr. Chew held clinical research and medical positions with Johnson & Johnson Company and Rhone-Poulenc Roer Corporation. In addition to his academic experience that includes positions as Medical Director at Saint Francis Memorial Hospital, and Assistant Clinical Professor (Oncology) at University of California, Davis, Dr. Chew also spent 14 years in the private practice of oncology and hematology. He holds a Bachelors Degree in Biochemistry from the University of California, Berkeley, and received his M.D. from the University of California, Los Angeles.

Company Overview: Techniclone Corporation is a biopharmaceutical company focused on the development, commercializing and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral technologies: Cotara(TM) Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). Cotara(TM), which binds to dead/decaying cells found in the core of solid tumors, is presently in a Phase II clinical trial in the U.S. for malignant glioma (brain cancer), and a Phase I/II clinical trial in Mexico City for the treatment of pancreatic, prostate and liver cancer. VEA's are monoclonal antibodies that increase tumor blood vessel permeation for enhanced uptake of chemotherapeutic agents versus normal tissues, while VTA's are agents that block the flow of oxygen/nutrients to a solid tumor's vascular network, causing clotting and necrosis. VTA's can also deliver a wide variety of therapeutic agents to a solid tumor, including biologic agents, toxins and radioisotopes. The Company also has a direct tumor targeting agent called Oncolym(R) for the treatment of advanced non-Hodgkin's B-cell Lymphoma which was recently licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym(R) clinical trial programs as well as marketing.

Additional information on the Company and its products can be found at www.techniclone.com.

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10Q for the quarter ended January 31, 1999 and Form 10K for the year ended April 30, 1998.